Outcomes4Me, a Boston-based developer of an AI-driven cancer care platform, announced the completion of a $21 million funding round led by London-based Salica Investments. The round included participation from all existing investors: Labcorp Venture Fund, Forecast Labs, Northpond Ventures, Sierra Ventures, Asset Management Ventures, IRA Capital, and Merstal LTD, bringing the company's total capital raised to $38 million.
The direct-to-patient platform currently serves more than 280,000 cancer patients, providing AI-enabled tools that integrate real-time clinical guidelines, genomic insights, medication and symptom tracking, clinical trial matching, and patient peer communities into a single interface.
Platform Integration and AI Capabilities
"AI will reshape cancer care, and this investment accelerates our ability to deliver personalized treatments and improved outcomes to patients at scale," said Maya R. Said, Sc.D., Founder and CEO of Outcomes4Me. "With more than 280,000 cancer patients using our AI-enabled platform, we're not just offering people diagnosed with cancer a tool, we're empowering them with intelligent, real-time insights that guide them through every step of their care."
The platform combines cutting-edge AI with oncology expertise to generate multimodal patient-level data enriched at the drug level. This approach enables the company to accelerate innovation in cancer care while driving improved patient outcomes and sustainable revenue growth.
Strong Market Adoption and Recognition
Since its commercial launch in 2022, Outcomes4Me has demonstrated significant revenue growth trajectory, reflecting increasing demand for personalized cancer-care solutions. Seven of the top 10 global cancer pharmaceutical companies are already among the company's customers, highlighting its market leadership position.
The company's innovation has garnered widespread recognition, generating more than 15 industry awards over the past three years, including being named a Fast Company World Changing Idea. Outcomes4Me ranked #12 on the Inc. Regionals Northeast 2025 list, jumping from #70 the previous year. Additionally, an independent peer-reviewed study published in Current Oncology identified Outcomes4Me as the highest quality application among over 3,000 applications for adults with cancer worldwide.
Strategic Expansion Plans
Amy Summy, Executive Vice President, Chief Marketing Officer and Consumer Lead for Labcorp, commented on the investment: "Outcomes4Me is an AI-driven pioneer in the oncology space, scaling rapidly in a market that demands smarter, personalized healthcare solutions. We are excited to support their digital platform as part of our deep commitment to help advance oncology care and improve patient outcomes."
The new funding will enable Outcomes4Me to accelerate market penetration across a broader range of cancer types, geographies, and global markets. The company plans to leverage its proprietary datasets and expand AI capabilities to drive more precise, real-time personalized treatment recommendations.
Revenue Growth Strategy
Outcomes4Me's business model focuses on partnering with life sciences companies to help them reach the right patient at the right time with the right action. The funding will support scaling revenue streams through new partnerships, international expansion, and innovative business models.
The company also aims to strengthen and scale collaborations with top-tier health systems and life sciences companies globally while driving outcomes-based evidence generation and real-world data insights for improved treatment and care. As part of its trajectory to become the leading global digital health solution for cancer care, Outcomes4Me is making strategic moves toward international expansion with goals to impact global cancer care standards.
